Elicio Therapeutics Reports Updated Phase 1 Data for ELI-002 at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics, Inc.

Updated Phase 1 data show 16.3-month median recurrence-free survival (mRFS) and 28.9-month median overall survival (mOS) from full study population (n=25).
Strong correlation observed between T cell response and reduced risk of progression or death.
Event-driven interim analysis from randomized Phase 2 trial of ELI-002 7P expected in first half of 2025.
ELI-002 was well-tolerated with no Grade 3/4 adverse events or dose-limiting toxicities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.